The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma

Recurrent glioblastoma (rGBM) is a highly aggressive form of brain cancer that poses a significant challenge for treatment in neuro-oncology, and the survival status of patients after relapse usually means rapid deterioration, thus becoming the leading cause of death among patients. In recent years,...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-08, Vol.15 (17), p.4308
Main Authors: Liu, Xudong, Zhao, Zihui, Dai, Wufei, Liao, Kuo, Sun, Qi, Chen, Dongjiang, Pan, Xingxin, Feng, Lishuang, Ding, Ying, Wei, Shiyou
Format: Article
Language:English
Subjects:
Antigens
Apoptosis
Brain cancer
Brain research
Brain tumors
Cancer
Cancer therapies
Cancer vaccines
Care and treatment
Central nervous system
Chemotherapy
Chimeric antigen receptors
Clinical trials
Drug delivery systems
Glioblastoma
Glioblastoma multiforme
Health aspects
Immune checkpoint inhibitors
Immune system
Immunotherapy
Lymphocytes
Lymphocytes T
Medical prognosis
Medical research
Monoclonal antibodies
Oncology
Oncolysis
Patients
Prognosis
Proteins
Radiation therapy
Review
T cells
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recurrent glioblastoma (rGBM) is a highly aggressive form of brain cancer that poses a significant challenge for treatment in neuro-oncology, and the survival status of patients after relapse usually means rapid deterioration, thus becoming the leading cause of death among patients. In recent years, immunotherapy has emerged as a promising strategy for the treatment of recurrent glioblastoma by stimulating the body’s immune system to recognize and attack cancer cells, which could be used in combination with other treatments such as surgery, radiation, and chemotherapy to improve outcomes for patients with recurrent glioblastoma. This therapy combines several key methods such as the use of monoclonal antibodies, chimeric antigen receptor T cell (CAR-T) therapy, checkpoint inhibitors, oncolytic viral therapy cancer vaccines, and combination strategies. In this review, we mainly document the latest immunotherapies for the treatment of glioblastoma and especially focus on rGBM.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15174308